RA Capital Management »

Aeglea Biotherapeutics shares owned by RA Capital Management

Quarter-by-quarter ownership of Aeglea Biotherapeutics (SYRE) shares owned by RA Capital Management from 13F filings

Historical chart of RA Capital Management investment in Aeglea Biotherapeutics

Tip: Access up to 7 years of quarterly data

All positions including Aeglea Biotherapeutics held by RA Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Aeglea Biotherapeutics by RA Capital Management

Quarter filed Position value Share count Share price at filing
2025-12-31 $53M 1.6M 32.76

More positions owned by RA Capital Management

Ascendis Pharma A/s - SH (ASND)
Cidara Therapeutics SH (CDTX)
Rhythm Pharmaceuticals SH (RYTM)
Avidity Biosciences SH (RNA)
Vaxcyte SH (PCVX)
Sionna Therapeutics SH (SION)
Newamsterdam Pharma Co Nv SH (NAMS)
Tyra Biosciences SH (TYRA)
Wave Life Sciences SH (WVE)
Mineralys Therapeutics SH (MLYS)
Edgewise Therapeutics SH (EWTX)
Septerna SH (SEPN)
Nuvalent Inc-a SH (NUVL)
Disc Medicine SH (IRON)
Janux Therapeutics SH (JANX)

View all positions for RA Capital Management

Top funds holding Aeglea Biotherapeutics

FMR
BlackRock
Rtw Investments
Vanguard Group
Fairmount Funds Management
VR Adviser
Capital Research and Management Company - Division 3
Perceptive Advisors
Driehaus Capital Management
Commodore Capital
State Street Corporation
TCG Crossover Management
Tang Capital Management
Geode Capital Management
Braidwell

View all funds holding Aeglea Biotherapeutics